Kenvue (KVUE) stock nudges up as fresh deal scrutiny hits — and the spread traders are watching

Kenvue (KVUE) stock nudges up as fresh deal scrutiny hits — and the spread traders are watching

New York, Jan 8, 2026, 10:57 EST — Regular session

  • Kenvue shares rose in morning trade as deal chatter resurfaced around its pending sale to Kimberly-Clark
  • A shareholder law firm said it was reviewing the transaction and the process behind it
  • Traders are watching the gap between Kenvue’s price and the value implied by the cash-and-stock offer ahead of a late-January vote

Kenvue Inc shares rose 0.8% to $16.87 in mid-morning trade on Thursday after shareholder law firm Kahn Swick & Foti said it was investigating the consumer health group’s pending sale to Kimberly-Clark. The firm said it is reviewing whether Kenvue’s board ran a fair process and secured the best price for shareholders. PR Newswire

The move matters now because Kenvue’s stock has been trading like a deal situation, not a stand-alone story, as investors handicap closing odds and timing. Merger arbitrage — buying the target while hedging the buyer — can keep shares anchored near the offer value, but the gap tends to widen when the finish line is far out.

Under the terms announced in November, Kenvue shareholders would receive $3.50 per share in cash and 0.14625 Kimberly-Clark shares for each Kenvue share held at closing. With Kimberly-Clark up about 1% at $98.52, that package implies roughly $17.91 per Kenvue share, leaving about a 6% discount in Thursday’s trade. PR Newswire

Separately, Kenvue appointed Madhav Nayak as vice president and chief marketing officer for Asia-Pacific. Nayak called the role “an incredible opportunity” to help shape brands including Johnson’s, Neutrogena and Listerine in a “fast-growing” region, according to an account of his remarks. Storyboard18

Consumer staples were mixed on the day. Procter & Gamble rose 1.6%, Haleon slipped 0.4%, and Perrigo gained 1.6%.

Still, the deal’s long runway leaves Kenvue exposed to swings in Kimberly-Clark’s share price and any delays tied to approvals. The company has also faced litigation over products including Tylenol and talc-based baby powder, risks that can reprice quickly when headlines hit. Reuters

Stock Market Today

  • Vodafone Group remains potentially undervalued after 63% one-year jump, DCF analysis suggests
    January 9, 2026, 5:03 AM EST. Vodafone Group's shares trade at £1.0365 after a 63.4% one-year surge. A two-stage Discounted Cash Flow (DCF) analysis calculates an intrinsic value of €1.99 per share, implying a roughly 47.8% discount to the current price in euro terms. The model uses free cash flow to equity through 2035, with the latest twelve months showing €7.7 billion. Analysts' projections extend beyond coverage, guiding later-year assumptions. A quick P/S (price-to-sales) cross-check is cited to account for revenue stability in large telecoms. The result frames Vodafone as undervalued on cash-flow grounds, even as near-term stock moves and risk factors stay in focus for investors reassessing value in established names.
AMD stock falls in regular trading as CES AI chip push meets profit-taking ahead of Feb. 3 earnings
Previous Story

AMD stock falls in regular trading as CES AI chip push meets profit-taking ahead of Feb. 3 earnings

Sandisk Corporation stock slides 11% as CES rally cools; BofA lifts target to $390
Next Story

Sandisk Corporation stock slides 11% as CES rally cools; BofA lifts target to $390

Go toTop